Global Branded Generics Market Size By Type (Oral, Parenteral), By Application (Oncology, Cardiovascular Diseases), By Region, And Segment Forecasts, 2023 to 2032

The Global Branded Generics Market was valued at USD 288.4 billion in 2023 and is projected to surpass USD 520.1 billion by 2031, growing at a CAGR of 7.8% during the forecast period from 2023 to 2031. Branded generics are off-patent drugs sold under a proprietary brand name and are especially prominent in price-sensitive and emerging markets. The market is being driven by patent expirations of blockbuster drugs, increasing demand for affordable medications, and the rapid growth of healthcare infrastructure in developing regions. Additionally, pharmaceutical companies are investing in branded generics to sustain revenue streams amid declining R&D productivity and rising regulatory challenges for novel drug approvals.

Drivers

1. Patent Expiry of Key Drugs:

Major pharmaceutical companies are facing patent cliffs, which has opened up opportunities for generic manufacturers to produce branded equivalents, boosting the growth of this market.

2. Cost-Effectiveness and Consumer Trust:

Branded generics offer the same therapeutic effects as originator drugs but at a lower cost, coupled with the perceived reliability of a branded label, especially in developing nations where physician prescriptions are influenced by brand familiarity.

3. Expanding Healthcare Access in Emerging Markets:

Government initiatives to improve healthcare coverage and accessibility in countries like India, Brazil, and Indonesia are fueling demand for affordable branded medicines.

Restraints

1. Regulatory Hurdles and Price Controls:

Varying approval standards and strict pricing regulations in different countries can delay market entry and reduce profitability for branded generics manufacturers.

2. Intense Market Competition:

The branded generics market is highly fragmented with numerous local and international players, making differentiation difficult and often leading to price wars.

Opportunity

1. Rising Demand for Chronic Disease Treatments:

With the global rise in chronic illnesses such as diabetes, hypertension, and cardiovascular diseases, the long-term demand for branded generics is expected to soar due to their affordability and effectiveness.

2. Strategic Collaborations and Mergers:

Pharmaceutical companies are increasingly partnering or acquiring regional players to strengthen their presence in key emerging markets, presenting growth potential through expanded product portfolios and distribution networks.

Market by System Type Insights

Based on system type, the oral solid dosage (OSD) form segment held the largest market share in 2023. Tablets and capsules dominate due to their ease of manufacturing, cost-effectiveness, and patient compliance. However, the injectables segment is witnessing the fastest growth rate, driven by increasing demand for biologics and biosimilars in therapeutic areas like oncology and auto-immune diseases.

Market by End-Use Insights

By end-use, retail pharmacies emerged as the largest distribution channel, capturing more than 45% of the market in 2023. Their broad accessibility, coupled with direct-to-consumer sales strategies, makes them a favored choice. Meanwhile, hospital pharmacies are gaining traction due to rising institutional procurement of generics for chronic and acute treatment.

Market by Regional Insights

Geographically, Asia-Pacific dominated the market in 2023, led by India and China, which are major manufacturing hubs with favorable pricing and regulatory environments. Latin America and Eastern Europe are also emerging as lucrative regions due to supportive public health programs. North America remains a significant market due to increasing generic drug adoption and ongoing cost-containment efforts by insurers and healthcare providers.

Competitive Scenario

Key players in the global branded generics market include Teva Pharmaceutical Industries Ltd., Mylan N.V. (now part of Viatris Inc.), Novartis AG (Sandoz), Lupin Limited, Sun Pharmaceutical Industries Ltd., Cipla Ltd., Dr. Reddy’s Laboratories, Pfizer Inc., Sanofi S.A., and Aurobindo Pharma Ltd. These companies are focusing on expanding their branded generic portfolios, entering emerging markets, and investing in biosimilars to diversify their revenue streams.

Scope of Work – Global Branded Generics Market

Key Market Developments

2023: Teva launched a new portfolio of branded generics in Latin America to strengthen its regional presence amid rising demand for affordable medicines.

2024: Viatris formed a joint venture with a leading Chinese firm to scale distribution of branded generics in tier-2 and tier-3 cities.

2025: Novartis’ Sandoz division introduced high-demand cardiovascular branded generics in South Africa as part of its access initiative program.

FAQs

1) What is the current market size of the Global Branded Generics Market?

The market was valued at USD 288.4 billion in 2023.

2) What is the major growth driver of the Global Branded Generics Market?

The major growth driver is the patent expiration of branded drugs and the rising demand for affordable medicines.

3) Which is the largest region during the forecast period in the Global Branded Generics Market?

Asia-Pacific is expected to dominate due to its robust manufacturing capabilities and large patient population.

4) Which segment accounted for the largest market share in the Global Branded Generics Market?

The oral solid dosage (OSD) segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Branded Generics Market?

Teva, Viatris, Novartis (Sandoz), Sun Pharma, Lupin, Cipla, Dr. Reddy’s, Pfizer, Sanofi, and Aurobindo Pharma are key players in the market.